Browse the evidence

Lifestyle modification (smoking cessation, diet, exercise) is the fundamental basis for managing cardiovascular risk in perimenopausal women with type 2 diabetes, though long-term weight maintenance is difficult.

Stop smoking, eat more veggies, limit salt, and move 30 minutes a day. These are the most important steps you can take. However, if you struggle to keep the weight off or control your numbers, don't blame yourself. You likely need medication (like SGLT2s or GLP-1s) to help you succeed.

Tirzepatide (10 mg and 15 mg) achieves statistically equivalent total body weight loss to sleeve gastrectomy (SG), with both interventions demonstrating superior efficacy compared to other pharmacotherapies.

If you are an adult with obesity, high-dose Tirzepatide (10-15 mg weekly) can help you lose approximately 21% of your body weight, which is statistically the same amount of weight loss achieved by sleeve gastrectomy surgery. This makes it a highly effective non-surgical option, though it requires weekly injections and lifestyle modifications.

Behavioral weight management interventions delivered in primary care result in statistically significant weight loss (mean difference -2.3 kg) and waist circumference reduction (-2.5 cm) compared to no treatment or minimal intervention at 12 months.

If you have obesity, ask your primary care doctor about a behavioral weight management program. Look for programs that offer at least 12 contacts (visits or calls) over a year. These programs, delivered by nurses, health coaches, or GPs, have been proven to help adults lose an average of 2.3 kg and reduce waist size, which brings health benefits even if the number seems modest.

Interventions providing 12 or more contacts result in significantly greater weight loss than those providing fewer than 12 contacts.

When choosing a weight management program, prioritize one that offers at least 12 interactions (calls or visits) over the course of the year. More contact leads to better weight loss results, regardless of whether the provider is a doctor, nurse, or health coach.

Low-carbohydrate diets improve glycemic control (HbA1c) more than balanced-carbohydrate diets in overweight/obese adults with type 2 diabetes.

If you have type 2 diabetes, a low-carb diet is likely to lower your HbA1c more effectively than a balanced diet. Work with your doctor to adjust medications as your blood sugar improves.

Once-daily oral semaglutide 50 mg significantly reduces ad libitum energy intake, body weight, and appetite while improving control of eating in adults with obesity, without delaying gastric emptying at steady state.

Take oral semaglutide 50 mg once daily, following the specific dose-escalation schedule (starting at 1.5 mg and increasing every 4 weeks). Do not eat or drink (except water) for 6 hours before taking the tablet, and wait 30-45 minutes after taking it before your first meal. This regimen significantly reduces your energy intake and body weight primarily by lowering appetite and improving control over eating, rather than by slowing down your digestion.

Low-carbohydrate diets (LCDs) produce greater short-term weight loss and improved metabolic markers (HbA1c, insulin sensitivity) compared to low-fat or high-carbohydrate diets in adults with obesity or type 2 diabetes.

If you have obesity or type 2 diabetes, reducing carbohydrate intake (to <40% of calories or <20-40g/day initially) is a clinically supported strategy for losing weight and improving blood sugar control more effectively than standard low-fat diets in the short term. Expect some initial side effects like fatigue or 'keto flu' which usually resolve as your body adapts. Monitor your health markers with a doctor.

Maintaining ≥7% weight loss one year after a 12-week intensive lifestyle intervention (ILI) significantly reduces the 10-year incidence of diabetic nephropathy in patients with diabetes.

For patients with diabetes and obesity, aiming for at least 7% weight loss within the first year of a structured lifestyle program is critical. This specific threshold is associated with a significantly lower risk of developing kidney disease (nephropathy) over the next decade. Focus on sustainable dietary and exercise changes to achieve this initial loss, as maintaining it provides long-term organ protection.

Isocaloric substitution of ultra-processed foods (NOVA 4) with minimally processed foods and culinary ingredients (NOVA 1+2) is associated with greater weight loss, body fat reduction, and trunk fat reduction in individuals following an energy-restricted diet.

If you are trying to lose weight, focus on swapping ultra-processed foods (like packaged snacks, sugary drinks, and processed meats) for minimally processed foods (like whole fruits, vegetables, and whole grains) while keeping your total calories the same. This swap can help you lose more weight and body fat than just counting calories alone.

Tirzepatide (5, 10, and 15 mg once weekly) produces significantly greater weight loss than both placebo and GLP-1 receptor agonists (semaglutide, dulaglutide) in adults with overweight or obesity.

If you have overweight or obesity, tirzepatide (administered once weekly) is a highly effective pharmacological option for weight loss, outperforming both placebo and existing GLP-1 medications like semaglutide. Expect significant weight reduction (up to ~12.5 kg with the highest dose) and a higher likelihood of achieving major weight loss milestones (5%, 10%, 15%). Be prepared for potential gastrointestinal side effects (nausea, diarrhea), which are common but often manageable and comparable to other drugs in this class. Consult a healthcare provider to determine if you are a candidate based on your BMI and health status.

Maintaining ≥ 7% weight loss at 1 year following a 12-week intensive lifestyle intervention (ILI) in patients with diabetes and obesity predicts sustained cardiometabolic improvements, including lower A1C and better lipid profiles, over 15 years.

For patients with diabetes and obesity, completing a structured lifestyle program and maintaining at least 7% of their body weight loss after one year is a critical milestone. This specific level of sustained weight loss is strongly associated with better long-term blood sugar control (A1C) and lipid profiles over 15 years, even if the initial intensive program ends. Focus on maintaining that initial loss rather than expecting continuous rapid weight loss.

Once-weekly tirzepatide (5, 10, or 15 mg) combined with lifestyle intervention produces statistically significant and clinically meaningful body weight reductions (up to -22.4%) and improvements in cardiometabolic risk factors in Japanese adults with obesity or overweight.

For Japanese adults with obesity or overweight, adding once-weekly tirzepatide to a standard lifestyle program (calorie deficit and exercise) leads to substantial weight loss (up to ~22%) and improves heart health markers like blood pressure and cholesterol. While injections are required, side effects like nausea are common but usually mild and temporary. This treatment is specifically approved and effective for this demographic, who may face higher health risks at lower BMIs compared to other ethnicities.

A remote culinary medicine program integrated with health coaching produces significant, sustained weight loss (approx. 4%) and fat mass reduction in adults with overweight/obesity over 12 months.

To lose weight sustainably, focus on building cooking skills and confidence rather than just counting calories. This program uses weekly 30-minute remote coaching to help you set small, achievable cooking goals and track progress. It works by making home cooking easier and more appealing, leading to an average 4% body weight loss over a year without requiring a professional kitchen.

GPS-enabled physical activity interventions produce significant short-term reductions in body weight and body fat percentage in adults, with effects comparable to or exceeding those of combined physical activity and dietary interventions.

Use a GPS-enabled fitness tracker or app to monitor your daily movement. Focus on consistency rather than perfection. The data shows that short-term, consistent activity tracking (under 3 months) yields the best weight loss results. You do not necessarily need to add a strict diet plan if you are using a smart tracking system, as the behavioral feedback from the device alone can drive significant fat loss. Prioritize ease of use to maintain adherence.

A 12-week low-glycemic index (LGI) diet produces significantly greater reductions in waist circumference, LDL cholesterol, non-HDL cholesterol, and leptin, along with greater increases in GLP-1, compared to a matched low-energy diet (LED) in women with excess body weight, without causing a decline in resting metabolic rate.

To improve your metabolic health and reduce belly fat, switch to a low-glycemic index diet for 12 weeks. Focus on eating foods with a GI of 55 or less freely, limit moderate-GI foods to two servings a day, and avoid high-GI foods. You do not need to strictly count calories; eat until you are satisfied. This approach has been shown to lower bad cholesterol, reduce belly fat more effectively than standard dieting, and improve hormonal markers like GLP-1 without slowing down your metabolism.

Maintaining high cardiovascular health (defined by the AHA's Life's Simple 7 metrics: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure) is associated with a significant reduction in major cardiovascular disease events, with 70% of events attributable to low/moderate health and 2 million events potentially preventable annually if all US adults attained high health.

Focus on the 'Life's Simple 7': stop smoking, stay active, maintain a healthy weight, eat a heart-healthy diet, and keep your blood pressure, cholesterol, and blood sugar in check. You don't need to be perfect; moving from poor to moderate health on these metrics significantly lowers your risk of heart disease and stroke.

Daily consumption of 5 servings of fruit and vegetables (compared to 2 servings) is associated with lower total mortality, cardiovascular disease mortality, cancer mortality, and respiratory disease mortality.

Aim to eat 5 servings of fruits and vegetables every day. This specific intake level is linked to significantly lower risks of dying from heart disease, cancer, and respiratory issues compared to eating only 2 servings.

Physical activity reduces the risk of cardiovascular disease mortality, all-cause mortality, breast cancer, prostate cancer, and depression in adults aged 60 and older.

If you are over 60, staying physically active can significantly lower your risk of heart disease, early death, certain cancers, and depression. Incorporate regular movement into your routine to gain these protective benefits.

Structured exercise combined with dietary support and behavior therapy is an effective intervention for managing obesity in cancer survivors, while GLP-1 analogues and bariatric surgery offer rapid weight loss for selected cases.

Cancer survivors with obesity should prioritize structured exercise, dietary changes, and behavior therapy as the primary management strategy. For those needing more rapid weight loss, GLP-1 analogues or bariatric surgery may be considered, but lifestyle changes remain the foundation of care.

Intensive lifestyle intervention in adults with type 2 diabetes and overweight/obesity produces moderate, sustained weight loss and cardiovascular risk factor control, with significant cardiovascular benefits observed specifically in patients achieving >10% weight loss or >2 MET fitness increase in the first year.

For adults with type 2 diabetes, simply 'trying' lifestyle changes may not be enough to protect your heart. You need to aim for a significant result: losing at least 10% of your body weight or significantly increasing your physical fitness (measured in metabolic equivalents) within the first year. If you achieve this threshold, you are much more likely to see a reduction in cardiovascular outcomes compared to those who maintain their weight or fitness levels.

Metabolic surgery (bariatric surgery) is recommended for patients with type 2 diabetes and BMI ≥40 kg/m2, or BMI 35.0-39.9 kg/m2 without durable weight loss, and should be considered for BMI 30.0-34.9 kg/m2 without similar improvements, offering superior glycemic control and cardiovascular risk factor reduction compared to lifestyle/medical interventions.

If you have type 2 diabetes and a BMI of 30 or higher, metabolic surgery is a highly effective option, especially if other weight loss methods have failed. It offers superior glycemic control and significant reductions in cardiovascular risk factors. While there are short-term risks, perioperative mortality is low (0.03-0.20%), and the long-term benefits for health and mortality are substantial.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults with obesity by acting centrally to reduce appetite and peripherally to delay gastric emptying.

Semaglutide 2.4mg weekly, combined with a 500 kcal daily deficit and 150 minutes of weekly activity, produces an average 14.8% body weight loss over 68 weeks. Expect gastrointestinal side effects like nausea, which are common but often manageable.

Combining supervised exercise with GLP-1 receptor agonist (liraglutide) during weight loss maintenance significantly improves the sustainability of weight loss and body composition one year after treatment termination compared to using GLP-1 receptor agonist alone.

If you are using GLP-1 medications (like liraglutide or semaglutide) for weight loss, do not rely on the medication alone for long-term maintenance. The study shows that stopping the medication leads to significant weight regain. To prevent this, you must incorporate supervised exercise (specifically vigorous cycling and circuit training) during your treatment phase. This combination builds the behavioral and physiological resilience needed to maintain your weight loss even after you stop the medication.

Aging is associated with 'anabolic resistance,' where older adults require more protein to stimulate muscle protein synthesis (MPS) compared to younger adults, contributing to sarcopenia.

As you age, your muscles become less responsive to protein. To build or maintain muscle, you likely need 1.5 to 2 times more high-quality protein per meal than younger people do. Combine this with resistance exercise to overcome this 'anabolic resistance.'